This functionality is implemented using Javascript. It cannot work without it, etc...

Estamos cargando la información...

Saltar al contenido

Políticas Médicas

Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.

Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.

ID Título Última Revisión Siguiente Revisión Descripción Acceso
M5.001.001 Viscosupplementation Therapy For Knee May 14, 2025 May 20, 2026 Viscosupplementation therapy is part of the therapy used in the treatment of osteoarthritis of the knee.... Ver
M5.001.002 Rituximab May 14, 2025 May 20, 2026 Rituximab is a genetically engineered chimeric murine/human monoclonal igg1 kappa antibody directed against... Ver
M5.001.003 Trastuzumab – Trastuzumab Biologics May 14, 2025 May 20, 2026 Trastuzumab is a monoclonal antibody, one of a group of drugs designed to attack specific cancer cells.... Ver
M5.001.005 Bevacizumab May 14, 2025 May 20, 2026 Bevacizumab is a humanized monoclonal antibody directed against vascular endothelial growth factor a... Ver
M5.001.006 G-Csf Filgrastim May 14, 2025 May 20, 2026 White blood cell growth factors, also known as granulocyte colony stimulating factors (g-csf), are... Ver
M5.001.007 Somatuline® Depot; Lanreotide May 14, 2025 May 20, 2026 Somatuline® depot; lanreotide is used to treat people with acromegaly (condition in which the body... Ver
M5.001.008 Simponi ARIA® (golimumab) May 14, 2025 May 20, 2026 Golimumab is in a class of drugs called biologics. golimumab is a treatment for adults with moderate to... Ver
M5.001.009 Stelara® (ustekinumab) May 14, 2025 May 20, 2026 Stelara is a human igg1κ monoclonal antibody that binds with high affinity and specificity to the p40... Ver
M5.001.010 Infliximab May 14, 2025 May 20, 2026 Infliximab (remicade®) is a tumor necrosis factor α (tnf-α) blocking agent approved by the... Ver
M5.001.011 Erythropoiesis Stimulating Agents May 14, 2025 May 20, 2026 Endogenous erythropoietin is a glycoprotein hematopoietic growth factor that regulates hemoglobin levels in... Ver
M5.001.012 Vascular Endothelial Growth Factor Inhibitors for the Treatment of Ophthalmological Diseases May 14, 2025 May 20, 2026 Vascular endothelial growth factor has been implicated in the pathogenesis of a variety of ocular vascular... Ver
M5.001.013 Ruconest May 14, 2025 May 20, 2026 C-1 esterase inhibitor protein is one of nine complement proteins found in the blood that works with the... Ver
M5.001.014 Immune Globulin May 14, 2025 May 20, 2026 Immune globulin (also referred to as gamma globulin or immunoglobulin) is a therapeutic compound prepared... Ver
M5.001.015 Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adult Patients May 14, 2025 May 20, 2026 Hereditary transthyretin-mediated amyloidosis (hattr) is a rare, progressive, and fatal autosomal dominant... Ver
M5.001.016 Lumasiran for Primary Hyperoxaluria Type 1 May 14, 2025 May 20, 2026 Primary hyperoxalurias are a group of rare genetic diseases. there are 3 subtypes each resulting in the... Ver
M5.001.017 Hemophilia Antihemophilic Factor May 14, 2025 May 20, 2026 The hemophilias are a group of related bleeding disorders that most commonly are inherited. inherited... Ver
M5.001.018 Nucala® (mepolizumab) May 14, 2025 May 20, 2026 Mepolizumab is an interleukin-5 antagonist monoclonal antibody (igg1 kappa) for the add-on maintenance... Ver
M5.001.019 Fasenra® (benralizumab) May 14, 2025 May 20, 2026 Benralizumab is an interleukin-5 antagonist monoclonal antibody (igg1 kappa) for the add-on maintenance... Ver
M5.001.020 Givosiran for Acute Hepatic Porphyria May 14, 2025 May 20, 2026 Acute hepatic porphyria (ahp) is a rare disease with a prevalence of 5 to 10 cases/100,000 people in the us... Ver
M5.001.021 Biological Treatments for Refractory Myasthenia Gravis May 14, 2025 May 20, 2026 Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating motor weakness... Ver
787-277-6653 787-474-6326